Start page Newsroom All news Newsroom type All Releases Articles year All years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® (25/200/100; 37.5/200/150 and 50/200/200 mg strengths) in the United States 12/11/2008 Stock exchange release Orion sues Wockhardt USA, Inc. and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo® 12/8/2008 Stock exchange release Orion to renew operational model of pharmaceutical R&D. Negotiation proposal on reduction of up to 300 employees in Finland 11/19/2008 Stock exchange release Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan® 11/12/2008 Stock exchange release Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan® 11/12/2008 Stock exchange release Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® in the United States 11/3/2008 Stock exchange release Composition of the Nomination Committee of Orion Corporation 10/29/2008 Stock exchange release Orion Corporation's publication schedules for financial reporting in 2009 10/28/2008 Stock exchange release Orion Group Interim Report 1-9/2008 10/28/2008 Stock exchange release Orion comments on new ANDA by Sun Pharma Global, Inc. for generic entacapone (Orion's proprietary drug Comtan®) in the United States 10/7/2008 Stock exchange release Orion updates progress with dexmedetomidine trials 9/12/2008 Stock exchange release Orion Group Interim Report 1-6/2008 8/5/2008 Stock exchange release Orion Corporation publishes Interim Report Q2/2008 on 5 August 2008 7/23/2008 Stock exchange release Orion's marketing rights for Paclical® Vet (paclitaxel) expanded European-wide 6/25/2008 Press release Orion receives rights for incontinence drug Kentera® from Recordati 5/30/2008 Press release Orion has decided not to continue the development of a new COMT inhibitor candidate 5/9/2008 Stock exchange release Orion Group Interim Report 1-3/2008 4/25/2008 Stock exchange release Orion seeking broader indication for Stalevo 4/15/2008 Stock exchange release
